Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

BUY
$161.01 - $317.85 $125,265 - $247,287
778 Added 21.85%
4,338 $1.37 Million
Q3 2023

Nov 06, 2023

SELL
$164.66 - $218.08 $435,525 - $576,821
-2,645 Reduced 42.63%
3,560 $601,000
Q2 2023

Jul 27, 2023

BUY
$176.32 - $240.22 $212,289 - $289,224
1,204 Added 24.08%
6,205 $1.35 Million
Q1 2023

May 02, 2023

BUY
$161.33 - $204.36 $73,082 - $92,575
453 Added 9.96%
5,001 $908,000
Q4 2022

Feb 10, 2023

BUY
$191.53 - $236.82 $4,979 - $6,157
26 Added 0.57%
4,548 $893,000
Q4 2022

Feb 09, 2023

BUY
$191.53 - $236.82 $313,534 - $387,674
1,637 Added 56.74%
4,522 $888,000
Q3 2022

Nov 02, 2022

SELL
$123.79 - $277.42 $28.7 Million - $64.4 Million
-232,182 Reduced 98.77%
2,885 $649,000
Q2 2022

Aug 01, 2022

SELL
$93.97 - $143.33 $11.6 Million - $17.7 Million
-123,683 Reduced 34.48%
235,067 $29.7 Million
Q1 2022

May 04, 2022

BUY
$98.9 - $132.37 $7.56 Million - $10.1 Million
76,418 Added 27.07%
358,750 $45.5 Million
Q4 2021

Feb 07, 2022

BUY
$110.64 - $159.4 $31 Million - $44.6 Million
279,938 Added 11693.32%
282,332 $37 Million
Q3 2021

Nov 02, 2021

SELL
$101.2 - $125.87 $11,334 - $14,097
-112 Reduced 4.47%
2,394 $293,000
Q2 2021

Aug 03, 2021

SELL
$107.45 - $135.95 $316,547 - $400,508
-2,946 Reduced 54.04%
2,506 $286,000
Q1 2021

May 04, 2021

SELL
$95.46 - $133.08 $244,663 - $341,084
-2,563 Reduced 31.98%
5,452 $655,000
Q4 2020

Feb 01, 2021

BUY
$75.23 - $109.23 $213,653 - $310,213
2,840 Added 54.88%
8,015 $814,000
Q3 2020

Nov 09, 2020

BUY
$71.31 - $109.74 $369,029 - $567,904
5,175 New
5,175 $400,000
Q2 2020

Aug 07, 2020

SELL
$62.14 - $117.21 $126,019 - $237,701
-2,028 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$11.44 - $123.99 $11,600 - $125,725
1,014 Added 100.0%
2,028 $192,000
Q3 2019

Nov 12, 2019

BUY
$16.05 - $27.35 $16,274 - $27,732
1,014 New
1,014 $17,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.